We recently compiled a list of the 13 Best Stocks to Invest In on Robinhood for Beginners. Cencora, Inc. is the next best Robinhood stock on this list. TheFly reported on March 23 that COR revealed that it has signed a binding agreement to acquire the retina division of EyeSouth Partners for $1.1 billion. Once the deal closes, EyeSouth’s affiliated retina physicians will become part of COR’s Retina Consultants of America, a leading management services organization. The acquisition integrates a strong regi ...

Core Insights - Cardinal Health (CAH) is experiencing a strong turnaround driven by pharmaceutical strength and a focused strategy, while McKesson (MCK) continues to demonstrate consistent execution in oncology and biopharma services [1][2][3] Business Performance - Cardinal Health's fiscal Q2 2026 revenues grew by 19% and operating earnings increased by 38%, supported by strong pharmaceutical demand [8][9] - McKesson's fiscal Q3 2026 revenues rose by 11% and earnings per share (EPS) increased by 16%, reflecting steady demand across its services [10] Growth Outlook - Cardinal Health raised its fiscal 2026 EPS guidance to $10.15-$10.35, indicating a growth of 23-26%, bolstered by efficiency initiatives and specialty expansion [11] - McKesson's guidance suggests a more predictable EPS growth of 17-19%, supported by its established oncology and specialty distribution services [12] Valuation Appeal - Cardinal Health is positioned as an attractive valuation opportunity with a Price to Earnings Forward 12 months (P/E F12M) ratio of 18.71, above the industry average of 17.14 [13][14] - McKesson trades at a premium P/E F12M ratio of 20.16, reflecting its consistent execution but may limit near-term upside compared to Cardinal Health [15] Business Mix & Strategy - Cardinal Health is reshaping its portfolio to focus on higher-margin segments, including specialty distribution and precision health, aiming to unlock long-term value [17] - McKesson's strategy is centered on a focused portfolio in oncology and biopharma services, providing stability but limited transformational upside [18] Shareholder Returns - Cardinal Health combines reliable dividends with improving free cash flow generation, reaching $1.8 billion year to date, enhancing its investor appeal [19] - McKesson emphasizes share buybacks and capital discipline, resulting in a declining share count and strong EPS growth [20] Conclusion - Cardinal Health is viewed as a compelling "value plus turnaround" story with improving fundamentals and strong growth potential, while McKesson remains a high-quality compounder with consistent performance but more incremental growth [25][26]

Key Takeaways MCK posted strong Q3 results with growth in specialty distribution, oncology services, and biopharma solutionsMCK saw 11% revenue growth and a 37% surge in oncology and multispecialty sales from expansion and buyout.MCK faces margin pressure in core distribution and weak Medical-Surgical performance with profit down 10%.McKesson (MCK) reported strong third-quarter fiscal 2026 results, driven by robust growth in specialty distribution, oncology services and biopharma solutions. Continued operat ...

Core Insights - Cardinal Health (CAH) demonstrated strong performance in fiscal Q2 2026, with revenues from its Pharmaceutical and Specialty Solutions segment increasing by 19% year over year to $61 billion, and profits rising by 29% to $687 million, solidifying its role as the main earnings driver for the company [1][9]. Growth Drivers - The growth was primarily driven by robust pharmaceutical demand, momentum in specialty drugs, and enhanced operational efficiency within the distribution network. Notably, GLP-1 medications contributed approximately 6 percentage points to revenue growth during the quarter, indicating strong demand for these therapies [2][3]. - Cardinal Health's focus on specialty pharmaceuticals is a significant catalyst for growth, with expectations that specialty revenues will surpass $50 billion in fiscal 2026, highlighting the segment's increasing importance [3][4]. - The Red Oak generics program has also been a key contributor, with healthy generic unit growth exceeding long-term expectations, providing a stable source of margin expansion [5]. - New customer onboarding and strong demand from existing clients have bolstered the pharmaceutical distribution platform, while technology investments have improved operational efficiency, supporting margins and enhancing customer experience [6][7]. Financial Outlook - Estimates for Cardinal Health's fiscal 2026 earnings have increased by 25.1% to $10.31 per share over the past year, with fiscal 2027 earnings improving by 10.6% to $11.40, reflecting positive sentiment towards the stock [8]. - The company raised its fiscal 2026 EPS outlook to a range of $10.15-$10.35, indicating a year-over-year growth of approximately 23-26% [13][21]. Competitive Landscape - Cardinal Health operates in a concentrated pharmaceutical distribution industry alongside competitors like McKesson (MCK) and Cencora (COR). Despite intense competition, Cardinal Health maintains a strong position due to its scale, supply-chain expertise, and diversified services [10][12]. - McKesson has reported strong results driven by growth in oncology services and biopharma solutions, while Cencora is expanding its specialty platform through acquisitions [10][11]. Price Performance - Cardinal Health's shares have surged by 73.5% over the past year, outperforming the industry growth of 15.9% and the S&P 500 Index's increase of 26%. The company has also outperformed peers McKesson and Cencora, which gained 45.3% and 37.7%, respectively [14]. - The shares currently trade at a forward 12-month price-to-earnings (P/E) ratio of 19.45X, higher than the industry average of 18.01X, indicating strong earnings visibility and guidance [18]. Conclusion - The Pharmaceutical and Specialty Solutions segment remains the primary growth engine for Cardinal Health, with strong specialty drug demand, a robust generics program, and improved operational efficiency supporting earnings momentum. The strategic focus on specialty distribution and physician services presents a durable long-term opportunity for the company [21][22][24].

Summary of McKesson Conference Call Company Overview - **Company**: McKesson Corporation - **Industry**: Healthcare and Pharmaceuticals Key Points and Arguments Leadership Transition - Britt Vitalone, CFO of McKesson, announced his retirement after eight years in the role, with a long tenure at the company [9][10] Financial Performance - McKesson has a strong track record of consistent performance over 190 years, focusing on capital allocation and building a differentiated asset portfolio [9][10] - Specialty revenues in FY25 were approximately $180 billion, with a compound annual growth rate of 18% over the last five years for specialty revenues [12][13] Specialty Business Insights - The growth in specialty products is driven by high innovation in drug research, particularly in oncology and multi-specialty areas [12][13] - McKesson serves over 14,000 providers across various specialties, enhancing their service offerings [13] CoverMyMeds and Access Solutions - CoverMyMeds has significantly outperformed due to the rise of GLP-1s, contributing around 11% to the revenue segment [15][18] - The company is expanding its capabilities to cover drugs under both pharmacy and medical benefits, enhancing access and affordability solutions [14][18] Negotiations and Market Changes - McKesson has successfully negotiated with manufacturers to maintain fair value for logistics and supply chain services, even amid changes like IRA negotiated drugs [21][22] - The company emphasizes its role as a financial intermediary, managing inventory and receivables for manufacturers [26][27] Impact of Geopolitical Events - McKesson has strategies in place to manage the impact of geopolitical events on commodity pricing, ensuring low-cost, high-quality drug supply [28][29] Biosimilars Strategy - Biosimilars are seen as a way to enhance access and provide lower-cost alternatives for patients and providers [30][31] - McKesson aims to partner with manufacturers to introduce biosimilars into their network [30][31] ClarusONE and Sourcing Capabilities - ClarusONE has been a successful venture for McKesson, improving sourcing capabilities and negotiating with manufacturers [36][39] - The company is partnering with domestic firms to enhance supply chain reliability for antibiotics [39] Independent Pharmacy Support - McKesson continues to support independent pharmacies through various services, addressing their unique needs and challenges [40][41] - The company provides reimbursement services to help independent pharmacies manage costs [42] Technology Integration and AI - RelayHealth serves as a backbone for pharmacy operations, integrating various components of McKesson's technology platform [44][45] - AI is being implemented across multiple areas, improving efficiency and case handling in customer service [45][46] Ontada and Clinical Research - Ontada serves as a central platform for US Oncology, managing EHR and providing insights for clinical purposes [47][49] - The partnership with Sarah Cannon Research Institute has expanded clinical trial capabilities within US Oncology [50] MedSurg Business Preparation - McKesson is preparing its MedSurg business for independence, focusing on leadership, capital structure, and operational performance [51][52] - The company is identifying growth opportunities in various channels, particularly in physician-affiliated health systems [59][60] MSO Acquisitions Integration - Integration of recent MSO acquisitions is progressing well, with a focus on leveraging McKesson's scale and solutions to enhance growth [61][64] Internal AI Priorities - McKesson is prioritizing internal AI investments to drive operational efficiencies and improve working capital management [69][70] Additional Important Insights - The company has made significant investments in technology and operational improvements, resulting in a notable reduction in operating expenses as a percentage of gross profit [70][71] - McKesson's focus on providing access and affordability remains central to its strategy, particularly in community care settings [40][41]

Summary of Cardinal Health Conference Call Company Overview - **Company**: Cardinal Health - **Industry**: Healthcare and Pharmaceuticals Key Points Fiscal Performance - **Strong First Half**: Cardinal Health reported a strong first half of fiscal 2026, driven by strong demand, execution, and investments across short-term, medium-term, and long-term objectives [8][10] - **Pharma Business Growth**: The pharma segment experienced a 19% revenue growth and a 29% profit growth, attributed to contributions from specialty and brand businesses, as well as strong volumes [8][9] - **Other Business Segments**: The "Other" segment, which includes Nuclear and Precision Health Solutions, At-Home, and OptiFreight, saw over 50% profit growth [9] - **Guidance Update**: EPS guidance was raised to $10.15-$10.35, with operating profit guidance also increased across all business segments [11][12] M&A Strategy - **Intentional M&A Approach**: Cardinal Health's M&A strategy focuses on leveraging competitive advantages and targeting specific therapeutic areas such as rheumatology, gastroenterology, and neurology [19][20] - **Ecosystem Building**: The company aims to build an ecosystem around therapy areas where it has historical strengths, enhancing its operational capabilities [21][22] - **Future M&A Plans**: Cardinal Health remains active in the M&A market, seeking lower multiple, tuck-in acquisitions while maintaining a disciplined capital allocation framework [44][47] Market Dynamics - **Healthcare Demand**: Despite macroeconomic challenges, Cardinal Health continues to see strong healthcare demand, supported by demographic trends [24] - **LOE Pipeline**: The company is positioned to benefit from an expected surge in loss of exclusivity (LOE) activity, with a strong collaboration with CVS through Red Oak Sourcing [25][26][27] - **Generic Pricing Trends**: There is a perception that generic pricing has stabilized, with consistent market dynamics and growing volumes [30][31] Regulatory Environment - **IRA Pricing Impact**: Cardinal Health expressed confidence in maintaining economic value with branded manufacturer partners despite upcoming IRA pricing changes [34][35] Investment in Other Segments - **Growth in Other Segments**: Cardinal Health is investing in its "Other" segments, expecting double-digit profit growth and enhancing operational capabilities [39][40] Financial Health - **Leverage and Cash Flow**: The company maintains a leverage ratio of 3.2x and expects to generate $3 billion-$3.5 billion in adjusted free cash flow this year [44][46] Management Outlook - **Positive Momentum**: The management team is optimistic about the company's growth trajectory and is closely monitoring the dynamic economic and regulatory environment [58][59] Additional Insights - **Community Focus**: Cardinal Health emphasizes its role in supporting community physicians and ensuring patient access to care, which is central to its operational strategy [22] - **Investment in Technology**: The company is investing in technology and automation to optimize its operations across various segments [39]

Summary of Cencora Conference Call Company Overview - **Company**: Cencora - **Industry**: Healthcare Technology and Distribution Key Points Financial Performance - Cencora reported a **21% growth** in its U.S. segment for the most recent quarter, indicating strong underlying business trends [2][3] - The company announced the acquisition of the remaining portion of **OneOncology**, enhancing its position in the specialty market [2][3] - Following the OneOncology acquisition, Cencora increased its consolidated guidance for the year by **3.5%**, with operating income growth guidance raised to **14%-16%** [3][4] Strategic Initiatives - The acquisition of OneOncology and **Retina Consultants of America (RCA)** is seen as a natural evolution of Cencora's specialty business, transitioning from distribution to Group Purchasing Organization (GPO) and now to Managed Service Organization (MSO) [3][6] - Cencora is focused on **growth-oriented investments** in specialty services, which are driving the company's growth [6][8] Market Trends - The oncology market is experiencing strong organic growth driven by factors such as an **aging population**, multi-therapy treatments, and new innovations including biosimilars [8][10] - Cencora's MSO strategy positions it well to capitalize on these trends, particularly in the physician-administered oncology market [8][10] Synergies and Operational Efficiency - With full ownership of RCA and OneOncology, Cencora aims to drive synergies between the two businesses, particularly in clinical trial capabilities and back-office operations [10][11] - The company emphasizes a long-term investment perspective, focusing on enhancing operational efficiencies and data analytics capabilities [12][16] Contracting and Pricing Strategy - Cencora's strategic global sourcing team successfully maintained gross profit dollars through effective contracting, despite challenges posed by the first round of IRA negotiated drugs [21][25] - The company has established terms in contracts to renegotiate in case of significant price changes, ensuring a defendable value proposition [27][28] Generics and Biosimilars Market - The generics market has shown **moderation in deflation**, with manufacturers prioritizing their portfolios, leading to a stable environment [36][38] - Cencora anticipates growth opportunities in both generics and biosimilars, which will complement branded innovation [38][39] Independent Pharmacies - Cencora has contributed to the sustainability of independent pharmacies by providing services and purchasing scale, allowing them to remain profitable [66][69] - The dynamics of independent pharmacy ownership have evolved, with multiple pharmacies often owned by a single entity leveraging distributor services [69] GLP-1 Market - The GLP-1 market is a significant growth area for Cencora, but it remains a minimally profitable segment, with no expected changes in profitability for fiscal year 2026 [70][71] Additional Insights - Cencora's focus on long-term investments and strategic acquisitions positions it well for future growth in the healthcare distribution sector [12][16] - The company is actively exploring bolt-on acquisitions to strengthen its specialty and pharmaceutical-centric strategies [19][20]

Summary of Cardinal Health 2026 Conference Call Company Overview - **Company**: Cardinal Health (NYSE: CAH) - **Event**: 2026 Conference Call - **Date**: March 09, 2026 Key Points Industry and Market Performance - **Broad-Based Growth**: Cardinal Health has experienced double-digit profit growth across all five business segments in Q2, driven by strong demand and operational execution [7][8] - **Specialty Business Growth**: The specialty business is projected to exceed $50 billion in revenue, with significant contributions from specialty distribution and biopharma services [11][12] - **Demographic Trends**: The aging American consumer is positively impacting demand for healthcare services, which is a key driver for Cardinal's growth [12] Business Segments and Strategies - **Core Pharma Business**: The core pharma segment is expected to see mid-teens growth in the second half of the year, influenced by new customer onboarding and acquisitions [12] - **Nuclear and Precision Health**: The company is investing in the Nuclear and Precision Health Solutions business, with over 70 therapeutics in the development pipeline, focusing on urology and oncology [77][78] - **MSO Investments**: Cardinal Health is enhancing its MSO (Managed Service Organization) capabilities, focusing on ancillary services that provide higher margins and diversified revenue streams [17][18] Financial and Operational Insights - **Contract Negotiations**: Cardinal Health has a robust history of negotiating contracts with suppliers, ensuring compensation for the value provided, especially in light of changes from the Inflation Reduction Act (IRA) [27][29] - **Margin Structure**: The company operates on a 1% margin for core distribution, emphasizing the essential service it provides to the healthcare system [36][37] - **Cost Management**: Cardinal Health has contractual provisions to manage commodity price fluctuations, with expectations of immaterial impact from rising oil prices in fiscal 2026 [46][47] M&A and Integration - **ADSG Acquisition**: The integration of the ADSG asset is progressing well, with expectations to exceed initial synergy targets. The acquisition is expected to enhance Cardinal's capabilities in diabetes care and home services [56][58] - **Future M&A Strategy**: Cardinal Health plans to continue disciplined capital allocation, focusing on organic investments and potential M&A opportunities that align with strategic needs [86] Conclusion and Outlook - **Strong Demand and Execution**: The management team expresses confidence in the company's future, citing strong demand and operational excellence as key factors for sustained growth [87] - **Long-Term Investment Focus**: Cardinal Health is committed to investing for future profit opportunities, looking beyond immediate quarterly results [87] Additional Insights - **Technology Integration**: The Specialty Networks acquisition enhances Cardinal's analytical capabilities and connectivity within the healthcare ecosystem, providing added value to both MSOs and independent practices [82][84] - **Community Provider Focus**: Cardinal Health emphasizes partnerships with community providers, aligning incentives to improve patient care while managing operational aspects [21][22] This summary encapsulates the key insights and strategic directions discussed during the Cardinal Health conference call, highlighting the company's performance, market dynamics, and future growth strategies.

Core Insights - ZeroStack Corp. has earned 3.2 million 0G tokens in staking rewards since initiating staking activities on January 21, 2026, reflecting an annual percentage yield (APY) of approximately 22% [1][2][3] - The U.S. dollar equivalent of the staking rewards earned is approximately $2.2 million for the period from January 21, 2026, to March 5, 2026, averaging about $50,000 per day [1][2] - The staking program is a foundational component of ZeroStack's portfolio, designed to generate recurring yield while enhancing the security and decentralization of blockchain networks [2] Company Overview - ZeroStack Corp. is the first Nasdaq-listed asset management company focused on decentralized AI, also operating a global pharmaceutical distribution business through its subsidiary, Phatebo GmbH [4]

Core Viewpoint - ZeroStack Corp. has secured a $6.5 million order for pharmaceutical distribution in Germany, highlighting its strong position in the European pharmaceutical supply chain and its ability to execute high-value distribution agreements [1][4]. Group 1: Company Overview - ZeroStack Corp. is the first Nasdaq-listed asset management company focused on decentralized AI and operates a global pharmaceutical distribution business through its subsidiary, Phatebo GmbH [6]. - Phatebo has been a portfolio company of ZeroStack for five years and is the largest revenue contributor, providing a reliable cash flow base [2]. Group 2: Order and Distribution - The $6.5 million order will be fulfilled through Phatebo, which has established logistics and regulatory expertise in the European healthcare market [1][3]. - The order underscores the strength of ZeroStack's pharmaceutical distribution platform and the trust placed in Phatebo by global healthcare leaders [4]. Group 3: Strategic Plans - As demand for innovative therapies grows in Europe, ZeroStack plans to leverage Phatebo's infrastructure and market relationships to expand its pharmaceutical distribution footprint [5].